Evidence map›Paper›PMID 42898100›Full record

ArticleiScience2026

Box C/D SNORD116-17 promotes prostate cancer progression by targeting the miR-206/E2F5 axis.

Xiuyi Pan, Yifan Kang, Jinjing Zhong, Ting Yu, Linmao Zheng, Yuyan Wei, Junya Tan, Ling Nie, Mengni Zhang, Ni Chen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiuyi PanDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Yifan KangDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Jinjing ZhongDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Ting YuDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Linmao ZhengDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Yuyan WeiDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Junya TanDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Ling NieDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Mengni ZhangDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Ni ChenDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Qiao ZhouDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Xueqin ChenDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small nucleolar RNAs (snoRNAs) are single-stranded non-coding RNAs found in eukaryotic nucleolus, and their aberrant expression is closely related to tumorigenesis. Box C/D SNORD116-17, a member of SNORD116 cluster, is highly expressed in prostate cancer tissues, though its biological function in this malignancy remains uncharacterized. Here, we found that SNORD116-17 is evident, stable, and highly expressed in prostate cancer cells and that its overexpression significantly promoted the proliferation, migration, and invasion of cancer cells. Bioinformatics prediction, RIP, RNA dot blot, and RNA-protein pulldown experiments revealed that miR-206 interacted with SNORD116-17, forming a complex with Argonaute 2. Subsequently, PCR and western blot experiments revealed that both miR-206 and SNORD116-17 regulated the expression of E2F transcription factor 5 (E2F5), a commonly studied oncogene in prostate cancer. In summary, SNORD116-17 contributes to prostate cancer progression by sponging with miR-206 through the ceRNA mechanism and upregulating the expression of E2F5.

Indexed as

E2F5miR-206prostate cancerSNORD116-17

Identifiers

PMID42898100
PMCPMC13677326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.